ObsEva Announces Management Change
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
GENEVA, Switzerland – July29, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s health, today announced the resignation of Jean-Pierre Gotteland, Chief Scientific Officer and Head of Research & Development, effective September 30, 2022. Dr. Gotteland will step down from the Company's Executive Committee, effective immediately.
“On behalf of the Board of Directors, Executive Committee, and all employees, I would like to thank Jean-Pierre for his contributions to ObsEva over the past seven years. It has been a pleasure to work together and we wish Jean-Pierre all the best in his future endeavors,” said Brian O’Callaghan, CEO of ObsEva.
ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a clinical pipeline with development programs focused on new therapies for the treatment of preterm labor and improving clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “might”, “ongoing”, “objective”, “plan”, “potential”, “predict”, “should”, “will”, “would”, or the negative of these and similar expressions, and are based on ObsEva’s current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties in the outcome and potential impact of the Company’s filing for a court-sanctioned moratorium, including with respect to ObsEva’s agreements with third parties, in ObsEva’s ability to successfully restructure its operations and refocus the Company’s development and commercialization strategy, and to cooperate with Kissei or other third parties on the completion of the linzagolix extension studies, in the conduct of clinical trials and clinical development, including the risk that the results of earlier clinical trials may not be predictive of the results of later stage clinical trials, related interactions with regulators, including interactions with the FDA during the New Drug Application process for linzagolix, ObsEva’s reliance on third parties over which it may not always have full control, and the capabilities of such third parties, the impact of the ongoing novel coronavirus outbreak and other geopolitical events, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with Securities and Exchange Commission (SEC) on March 10, 2022, in the Report on Form 6-K filed with the SEC on May 17, 2022 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at www.ObsEva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and, except as required by law, ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information, please contact:
CEO Administrative Contact
+41 22 552 1550
+1 (917) 969-3438
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sampo plc: Managers’ Transactions (Wahlroos/Alectoris AS)3.10.2022 08:55:00 CEST | Press release
SAMPO PLC MANAGERS’ TRANSACTIONS 3 October 2022 at 9:55 am Sampo plc: Managers’ Transactions (Wahlroos/Alectoris AS) Sampo plc (business code 0142213-3) has received the following notification under Article 19 of the Market Abuse Regulation. The transaction concerns the change of ownership in Alectoris AS. After the transaction, Wahlroos doesn’t have controlling interest in Alectoris AS. ____________________________________________ Person subject to the notification requirement Name: Björn Wahlroos Position: Member of the Board/Deputy member Issuer: Sampo plc LEI: 743700UF3RL386WIDA22 Notification type: INITIAL NOTIFICATION Reference number: 20225/5/4 ____________________________________________ Transaction date: 2022-09-27 Venue not applicable Instrument type: SHARE ISIN: FI0009003305 Nature of the transaction: GIFT, DONATION OR INHERITANCE (MADE) Transaction details (1): Volume: 570,000 Unit price: 0 N/A Aggregated transactions (1): Volume: 570,000 Volume weighted average price: 0 N/
Norsk Hydro: Status share buyback program3.10.2022 08:10:00 CEST | Press release
Please see below information about transactions made under the share buy-back program for Norsk Hydro ASA. Announcement date of the share buyback program: September 23, 2022 End date of the share buyback program: March 29, 2023 Overview of transactions: Date Aggregate daily volume (no. of shares) Volume weighted average price (NOK) Total transaction value (NOK) 26.09.2022177 00055.919 895 23827.09.2022170 00057.779 820 30528.09.2022178 00055.879 945 44729.09.2022170 00057.679 803 52630.09.2022170 00058.539 950 746Total transactions under the program:865 00057.1349 415 263 Following the above listed transactions, Norsk Hydro ASA owns a total of 17 317 403 shares, corresponding to 0.84% of Norsk Hydro ASA's share capital. Attachment: An overview of all the completed transactions under the program for the dates specified above is attached to this notification and available on www.newsweb.no. This is information that Norsk Hydro ASA is obliged to make public pursuant to the EU Market Abuse
Norsk Hydro: Status tilbakekjøp av egne aksjer3.10.2022 08:10:00 CEST | Pressemelding
Nedenfor er informasjon om transaksjoner foretatt under tilbakekjøpsprogrammet for Norsk Hydro ASA. Dato for når tilbakekjøpsprogrammet ble annonsert: 23. september 2022 Tilbakekjøpsprogrammets varighet: 29. mars 2023 Oversikt over transaksjoner: Date Aggregate daily volume (no. of shares) Volume weighted average price (NOK) Total transaction value (NOK) 26.09.2022177 00055,919 895 23827.09.2022170 00057,779 820 30528.09.2022178 00055,879 945 44729.09.2022170 00057,679 803 52630.09.2022170 00058,539 950 746Total transactions under the program:865 00057,1349 415 263 Etter gjennomføringen av overnevnte transaksjoner, eier Norsk Hydro ASA totalt 17 317 403 egne aksjer, tilsvarende 0,84% av Norsk Hydro ASAs aksjekapital. Vedlegg: En oversikt over alle gjennomførte handler under tilbakekjøpsprogrammet som er uført i overnevnte tidsperiode er vedlagt denne meldingen og tilgjengelig på www.newsweb.no. Denne opplysningen er informasjonspliktig i henhold til EUs Market Abuse Regulation og krav
Sampo plc’s share buybacks 30/09/20223.10.2022 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 03/10/2022 at 08:30 am Sampo plc’s share buybacks 30/09/2022 On 30/09/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)13,80843.79AQEU25,54143.80CEUX11,97643.85TQEX89,53443.80XHELTOTAL140,85943.80 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 10,853,632 Sampo A shares representing 2.04 per cent of the total number of shares in Sampo plc. Details of
Bavarian Nordic Enters Agreement with Country in Latin America on the Supply of Monkeypox Vaccines3.10.2022 07:30:00 CEST | Press release
First country in Latin America to sign a bilateral supply agreement thus expanding access to the monkeypox vaccine beyond the availability of vaccines through PAHOAdditional supply agreement also signed with PAHO to expand availability for its member countries COPENHAGEN, Denmark, October 3, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today an agreement with a Latin American country for the supply of the Company’s monkeypox vaccine. This is the Company’s first bilateral supply agreement for the vaccine in Latin America, outside the scope of the agreement entered with the Pan American Health Organization (PAHO) in August 2022, which has enabled access to the vaccine for its member countries. Through PAHO’s Revolving Fund for Access to Vaccines, the country will get access to its first monkeypox vaccines later this month and deliveries under the bilateral agreement will start in December 2022. Separately, following the initial supply agreement in August, PAHO has requested additiona